MB, Levis & Associates’s AstraZeneca AZN Stock Holding History

MB, Levis & Associates’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-745	Closed	-$137K	–	235
2025 Q4	$137K	Hold	745	–	–	0.06%	67
2025 Q3	$114K	Buy	745 +4	+0.5%	+$605	0.05%	75
2025 Q2	$103K	Hold	741	–	–	0.05%	86
2025 Q1	$109K	Buy	741 +11	+2%	+$1.59K	0.05%	82
2024 Q4	$95.7K	Hold	730	–	–	0.05%	88
2024 Q3	$114K	Buy	730 +4	+0.6%	+$646	0.06%	78
2024 Q2	$113K	Hold	726	–	–	0.06%	78
2024 Q1	$98.3K	Buy	726 +11	+2%	+$1.46K	0.05%	86
2023 Q4	$96.3K	Hold	715	–	–	0.06%	83
2023 Q3	$96.8K	Buy	715 +5	+0.7%	+$683	0.06%	81
2023 Q2	$102K	Hold	710	–	–	0.07%	81
2023 Q1	$98.6K	Buy	710 +10	+1%	+$1.34K	0.07%	80
2022 Q4	$94.9K	Buy	+700	New	+$87.8K	0.07%	76

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

MB, Levis & Associates's AZN Position: Q1 2026 in Review

MB, Levis & Associates sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 745 shares — an estimated $137K sold.

MB, Levis & Associates first reported a position in AZN in Q4 2022 and held it in 13 quarters. The position peaked at $137K in Q4 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

MB, Levis & Associates reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
MB, Levis & Associates sold 745 AstraZeneca shares in Q1 2026, an estimated $137K.
MB, Levis & Associates first reported a position in AstraZeneca in Q4 2022 and held it in 13 quarters.
MB, Levis & Associates's AstraZeneca position peaked at $137K in Q4 2025.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on MB, Levis & Associates's 13F filing for Q1 2026, filed 8 Apr 2026.